Researchers have identified a new type of synaptic plasticity they call behavioral timescale synaptic plasticity (BTSP). The study reveals how the entorhinal cortex sends instructive signals to the hippocampus and directs it to specifically reorganize the specific location and activity of a neural subset to achieve altered behavior in response to changes in environment and spatial cues.
Changes in the Retina Can Be Linked to Parts of the Brain of Healthy Subjects at Risk of Alzheimer’s
In cognitively healthy people with a genetic risk for Alzheimer's, retinal changes have been associated with alterations in the entorhinal cortex, hippocampus, and lingual gyrus. Researchers say retinal changes can be used to track changes in brain structures associated with Alzheimer's in those with genetic risk factors.
Wolframin-expressing excitatory neurons (WFS1) are more vulnerable in the entorhinal cortex.WFS1 may reduce tau-pathology and neurodegeneration via the regulation of stress response to the abnormal buildup of tau aggregates and the downstream protein degradation pathway.
Researchers have identified the characteristics of over 100 memory-sensitive neurons that play a key role in how memories are recalled in the brain.
Dopamine-controlled fan cells in the lateral entorhinal cortex are required for the formation of associative memories.
Researchers identified specific receptors for acetylcholine that reroute information flow through memory circuits in the hippocampus. The findings could have implications for the development of drugs to help enhance or protect memory from diseases associated with cognitive decline.
The cognitive map allows people to compute on the fly with limited information to solve abstract problems.
A new system within the brain uses for information processing and memory storage has been discovered. The findings provide novel insight into how the brain functions.
Depressed middle-aged carriers of the APOEe4 Alzheimer's genetic variant are at risk of developing tau accumulations in brain areas associated with emotion and memory.
Researchers launch the first-in-human phase 1 clinical trial to assess the safety and efficacy of a gene therapy which will deliver BDNF to the brains of those with Alzheimer's and mild cognitive impairment.
Two new studies advance understanding of how the brain encodes episodic memories. The findings have the potential to develop new avenues of treatment for memory loss associated with Alzheimer's disease and TBI.
Anxiety may accelerate the progression of mild cognitive impairment to Alzheimer's disease. Brain scans revealed patients who progressed from MCI to Alzheimer's disease had decreased volume in the hippocampus and entorhinal cortex.